After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Ultragenyx Pharmaceutical Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Ultragenyx Pharmaceutical Inc. is $4.06B. A total of 0.6 million shares were traded on the day, compared to an average of 874.80K shares.
In the most recent transaction, Sanders Corazon (Corsee) D. sold 584 shares of RARE for 40.98 per share on Jul 02 ’24. After the transaction, the Director now owns 12,009 company shares. In a previous transaction on Jun 12 ’24, Parschauer Karah Herdman sold 9,806 shares at 45.00 per share. RARE shares that EVP and Chief Legal Officer owns now total 57,981.
Among the insiders who sold shares, Sanders Corazon (Corsee) D. disposed of 1,737 shares on Jun 10 ’24 at a per-share price of $41.10. This resulted in the Director holding 7,248 shares of RARE after the transaction. In another insider transaction, Crombez Eric sold 354 shares at $43.66 per share on May 02 ’24. Company shares held by the EVP and Chief Medical Officer now total 48,431.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, RARE has a high of $54.56 and a low of $31.52.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $1.69, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.86.
